Pershing Square Activist Presentation Deck slide image

Pershing Square Activist Presentation Deck

Valeant's Franchises Valeant has built a diversified collection of platforms, including: Bausch & Lomb: 21% of sales(1) Global portfolio of consumer, prescription and surgical products ■ Organic growth 11% 2014, 7% YTD 2015 Gastrointestinal: 19% of sales(2) ■ Acquired in April 2015; prescriptions for largest product grew 25% last quarter Emerging Markets: 18% of sales(2) ■ Durable portfolio of branded generic products US Dermatology Rx: 16% of sales(²) ■ One of the largest Dermatology Rx businesses in the United States ■ Benefitting from recent product launches - Jublia, Onexton, RAM .08%, Luzu Neurology /Other: 15% of sales(2) ■ Older products, declining to ~10% of revenue in 2016 (1): Sales percentage from last reported public disclosure in Q2 2015, adjusted for estimated Salix inventory wholesaler reduction and Amoun acquisition. Excludes B&L emerging markets sales. (2): Sales percentages calculated from reported Q3 2015 sales and pro-forma estimated Salix inventory wholesaler reduction and Amoun acquisition. 29
View entire presentation